NSD2 and prostate carcinoma: Previous studies have shown that NSD2 inhibition potently enhances antigen processing and presentation via complex epigenetic remodeling of prostate cancer cells and that the IFN-γ signaling pathway increases MHC expression to stimulate antitumor immunity14.